secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-208999
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen Q1 2026 net loss $127.5M; cash $106.9M; on track for SZN-8141 IND in H2 2026
--------------------------------------------------------------------------------

- Net loss $127.5M ($11.65/sh) vs $27.0M ($7.43/sh) in Q1 2025, driven by non-cash fair value changes on warrants and tranche liability.
- Cash and equivalents $106.9M as of Mar 31, 2026, up from $89.2M at Dec 31, 2025.
- Received $5M milestone payment from Boehringer Ingelheim in April 2026 for SZN-413 GLP toxicology study progress.
- On track to submit IND for SZN-8141 for retinal diseases in H2 2026; preclinical data presented at ARVO.
- R&D expenses $9.3M (up $2.7M YoY) due to ophthalmology program costs; G&A $6.1M (up $2.1M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000119312526208999/0001193125-26-208999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000119312526208999/srzn-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-208999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer